Back to News
Market Impact: 0.15
Clearmind Medicine Briefs FDA On Patient Access At Psychedelic Hearing
Source: Nasdaq
Healthcare & BiotechRegulation & Legislation
Clearmind Medicine said Chief of Global Impact Mary-Elizabeth Gifford testified at an FDA hearing in Washington, D.C. on September 14, 2026, concerning the potential future therapeutic use of psychedelic drugs. The announcement signals engagement in the evolving regulatory discussion but provides no clinical, financial, or FDA approval outcome.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
neutral
Sentiment Score
0.10
Ticker Sentiment
CMND0.20
More News
- Amgen (AMGN) Bets on MariTide to Crack $120 Billion Obesity Market
- BTIG cuts Acumen Pharmaceuticals stock price target to $1 on trial results
- Wells Fargo raises Abbvie stock price target to $340 on pipeline
- Boris Vujčić: Integrated, open and resilient: Europe’s strengths in a fragmenting world
- Wells Fargo raises Regeneron stock price target to $925 on execution
- Citi initiates Vusion at buy, sees 84% upside on electronic shelf label growth